PIramed Ltd.
Executive Summary
PIramed Ltd. was incorporated in October 2001 to commercialize the findings of a research collaboration between three of Europe's leading cancer research institutes (the Ludwig Institute for Cancer Research, Cancer Research UK and the Institute for Cancer Research) and Yamanouchi Pharmaceutical Co. Ltd. The collaboration, initiated in 1995, identified a range of small molecule inhibitors of the PI3 Kinase (PI3K) family of lipid kinases-intracellular enzymes that are important in cell signalling pathways that influence a range of fundamental cellular activities including growth, migration, proliferation and survival, and are implicated in a number of diseases, including cancer, cardiovascular, neurodegenerative and immune-inflammatory diseases.